Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.16 USD | -1.69% | -5.69% | +9.38% |
Apr. 01 | Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 05 | North American Morning Briefing : S&P 500 Futures -2- | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 18.57M |
---|---|---|---|---|---|
Net income 2024 * | -9M | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.93
x | P/E ratio 2025 * |
-
| Employees | 1 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.61% |
Latest transcript on Alaunos Therapeutics, Inc.
1 day | -1.69% | ||
1 week | -5.69% | ||
Current month | -35.91% | ||
1 month | -39.27% | ||
3 months | -56.60% | ||
6 months | -22.12% | ||
Current year | +9.38% |
Managers | Title | Age | Since |
---|---|---|---|
Dale Hogue
CEO | Chief Executive Officer | 54 | Dec. 28 |
Director of Finance/CFO | 62 | 21-02-16 | |
Chief Tech/Sci/R&D Officer | 44 | 22-08-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jaime Vieser
BRD | Director/Board Member | 54 | 20-12-15 |
Holger Weis
CHM | Chairman | 61 | 20-12-15 |
Robert Postma
BRD | Director/Board Member | 70 | 21-02-04 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 1.16 | -1.69% | 9,252 |
24-04-24 | 1.18 | -1.67% | 30,377 |
24-04-23 | 1.2 | +10.09% | 46,815 |
24-04-22 | 1.09 | -2.68% | 38,305 |
24-04-19 | 1.12 | -8.94% | 49,732 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.38% | 18.89M | |
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |
- Stock Market
- Equities
- TCRT Stock